Under construction – not a live service
Sign in
WithdrawnNo phase

Expression of Sodium-glucose Co-transporter 2 in Human Heart

Reason given: authorization obsolete

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Trial details

Who runs it
University Hospital, Strasbourg, France
Trial code
NCT05830760
Record updated
23 December 2025
Original description
The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.Read full original descriptionShow less

Expression of Sodium Glucose Co-transporter2 in Myocardium From Patients With Aortic Valve Stenosis and With/Without Diastolic Heart Failure

The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.

Inclusion: adults over 18 years-old; Patient with surgical aortic valve stenosis, with or without heart failure, in two equal-sized groups (40 subjects in each group); Subjects affiliated with a social security health insurance plan; Subject able to understand the objectives and risks of the research and to give dated and signed informed consent.

Exclusion: Infective endocarditis in aortic stenosis; Severe coronary pathology associated with aortic stenosis; Impossible to give the subject informed information (subject in emergency situation, difficulties in understanding the subject, ...); Subject under legal protection; Subject under guardianship or curatorship; Pregnancy and/or breastfeeding.

ClinicalTrials.gov NCT05830760